Under construction – not a live service
Sign in
Taking people in ChinaPhase 3

Testing ivonescimab with docetaxel for advanced lung cancer after prior immunotherapy

Tests ivonescimab plus docetaxel against placebo plus docetaxel in adults with advanced lung cancer.

Key facts

Who runs it
Akeso
Where
Shanghai, ChinaSee the site
Trial code
Registry title
Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Status
Recruiting
Phase
Phase 3
People taking part
536 people, planned
Started
8 Jul 2025
Expected to end
Jun 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ivonescimab, docetaxel
  • Placebo, docetaxel
Record updated
9 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or spread non-small cell lung cancer that got worse after earlier chemotherapy and a PD-1/PD-L1 inhibitor.

Age
18 to 75 years
Sex
Men and women
Disease stage
Non-small cell lung cancer that is locally advanced or has spread (metastatic), with at least one lesion that can be measured.
Earlier treatment
Must have had platinum-based chemotherapy and PD-1/L1 inhibitors. Must not have had docetaxel before.
Biomarker or test result
Known actionable gene changes are not allowed.

Main reasons for not taking part

  • Small cell lung cancer
  • Other cancers within 3 years before randomization
  • Known actionable gene changes
  • Previous docetaxel treatment
  • Active autoimmune disease needing systemic therapy within 2 years

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures)
  • Age ≥ 18 years old and ≤ 75 years old at the time of randomization
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Expected life expectancy of at least 3 months
  • Histologically or cytologically confirmed diagnosis of NSCLC
  • Locally advanced or metastatic NSCLC (American Joint Committee on Cancer [AJCC] 8th edition)
  • Previously received systemic platinum-based chemotherapy and PD-1/L1 inhibitors
  • At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
  • Adequate organ function

Who cannot take part

  • Other malignancies within 3 years prior to randomization
  • Prior administration of any immunotherapy targeting immune mechanisms other than PD-1/PD-L1 inhibitors
  • Previous treatment with docetaxel
  • Active autoimmune disease requiring systemic therapy within 2 years prior to randomization
  • History of severe bleeding tendency or coagulation dysfunction
  • History of myocarditis, cardiomyopathy, and malignant arrhythmia
  • Histologic or cytopathologic evidence of the presence of small cell lung carcinoma
  • Known actionable genomic alterations

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in China

  • Shanghai East HospitalShanghai, ChinaContact: Caicun ZhouTaking people

About the trial

What the trial wants to find out

This is a Phase 3 Randomized, double-blind, Multicenter Study of Ivonescimab Combined with Docetaxel Versus Placebo Combined with Docetaxel in Patients with Locally advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) that has progressed on or after PD-(L)1 inhibitor-based therapy. The purpose of this study is to evaluate the efficacy and safety of ivonescimab versus placebo, combined with docetaxel in patients with advanced NSCLC.

The 2 groups in the trial

  • Ivonescimab and docetaxelTreatment being tested

    Treatment: Ivonescimab, docetaxel

  • Placebo and docetaxelExisting treatment, for comparison

    Treatment: Placebo, docetaxel

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Randomized, Double-blind, Multicenter Phase 3 Clinical Trial of Ivonescimab Versus Placebo, Combined With Docetaxel in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) That Has Progressed on or After PD-(L)1 Inhibitor-based Therapy
Plain-language title
Testing ivonescimab with docetaxel for advanced lung cancer after prior immunotherapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06928389, who can take part
Record updated
9 April 2026